Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomerica (BMRA) Liabilities and Shareholders Equity (2016 - 2026)

Biomerica's Liabilities and Shareholders Equity history spans 16 years, with the latest figure at $4.9 million for Q1 2026.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 33.87% to $4.9 million in Q1 2026 year-over-year; TTM through Feb 2026 was $23.7 million, a 25.38% decrease, with the full-year FY2025 number at $5.9 million, down 35.76% from a year prior.
  • Liabilities and Shareholders Equity hit $4.9 million in Q1 2026 for Biomerica, down from $6.0 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for BMRA hit a ceiling of $17.6 million in Q1 2022 and a floor of $4.9 million in Q1 2026.
  • Historically, Liabilities and Shareholders Equity has averaged $9.6 million across 5 years, with a median of $9.3 million in 2024.
  • Biggest five-year swings in Liabilities and Shareholders Equity: skyrocketed 31.56% in 2022 and later crashed 53.25% in 2023.
  • Tracing BMRA's Liabilities and Shareholders Equity over 5 years: stood at $9.9 million in 2022, then increased by 19.41% to $11.8 million in 2023, then plummeted by 38.52% to $7.3 million in 2024, then decreased by 17.05% to $6.0 million in 2025, then dropped by 19.16% to $4.9 million in 2026.
  • Business Quant data shows Liabilities and Shareholders Equity for BMRA at $4.9 million in Q1 2026, $6.0 million in Q4 2025, and $6.9 million in Q3 2025.